{"id":5765,"date":"2017-10-26T17:25:49","date_gmt":"2017-10-26T17:25:49","guid":{"rendered":"https:\/\/laforcedmd.com\/?p=5765\/"},"modified":"2022-05-03T18:19:34","modified_gmt":"2022-05-03T18:19:34","slug":"the-fda-closes-the-door-to-the-approval-of-ataluren","status":"publish","type":"post","link":"https:\/\/laforcedmd.com\/en\/the-fda-closes-the-door-to-the-approval-of-ataluren\/","title":{"rendered":"The FDA closes the door to the approval of ataluren"},"content":{"rendered":"<p><strong>The FDA has opted not to approve a treatment for DMD, ataluren from PTC Therapeutics. The FDA requires the PTC company to conduct yet another clinical trial in order to consider approval of the treatment. Stuart W. Peltz, CEO of PTC Therapeutics Inc., responded that a formal request called &#8220;dispute resolution&#8221; will be filed with the FDA next week.<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>This is the third time the FDA has rejected the PTC\u2019s application. This last refusal arrives a month after AdCom, an advisory committee of experts and parents. Here is what Stuart W. Peltz, CEO of PTC, communicated to the DMD community:<\/p>\n<p>&nbsp;<\/p>\n<blockquote><p>&#8220;We are extremely disappointed for the Duchenne community and strongly disagree with the agency&#8217;s conclusions,&#8221; said\u00a0Stuart W. Peltz, Ph.D., chief executive officer of\u00a0PTC Therapeutics. &#8220;We believe that this decision fails to consider the benefit-risk of ataluren and the high unmet medical need. Therefore, we plan to file a formal dispute resolution request next week.&#8221;<\/p>\n<p>-Stuart W. Peltz, CEO of PTC Therapeutics Inc.<\/p><\/blockquote>\n<p>&nbsp;<\/p>\n<h4>PTC Therapeutics continues to distribute ataluren to the families<\/h4>\n<p>The CEO, also reassured families currently receiving treatment through several clinical trial extension programs that they will continue to receive ataluren, throughout the &#8220;dispute resolution&#8221; appeal. A final decision about the distribution will be made following the outcome of the dispute resolution process. Regarding distribution for Canadian families, there is no information to suggest that there will be any change.<\/p>\n<p>&nbsp;<\/p>\n<h4>For more information, please consult:<\/h4>\n<ul>\n<li><a href=\"http:\/\/ir.ptcbio.com\/releaseDetail.cfm?ReleaseID=1045384\" target=\"_blank\" rel=\"noopener noreferrer\">Press release, PTC<\/a><\/li>\n<li><a href=\"https:\/\/seekingalpha.com\/news\/3303461-fda-action-date-today-ptc-therapeutics-filing-protest-nda-dmd-med-translarna-shares-5-percent\" target=\"_blank\" rel=\"noopener noreferrer\">PTC filling protest\u00a0<\/a><\/li>\n<li><a href=\"http:\/\/www.newsweek.com\/fda-decision-leaves-family-few-options-693005\" target=\"_blank\" rel=\"noopener noreferrer\">FDA decision leaves family few options<\/a><\/li>\n<li><a href=\"http:\/\/www.xconomy.com\/new-york\/2017\/10\/25\/no-charm-ptcs-duchenne-drug-rejected-by-fda-for-third-time\/\" target=\"_blank\" rel=\"noopener noreferrer\">No charm PTC Duchenne drug rejected<\/a><\/li>\n<li><a href=\"http:\/\/www.pharmatimes.com\/news\/fda_rejects_ptcs_dmd_drug_translarna_1209726\" target=\"_blank\" rel=\"noopener noreferrer\">PharmaTimes<\/a><\/li>\n<li><a href=\"http:\/\/www.raredr.com\/news\/fda-crl-ptc\" target=\"_blank\" rel=\"noopener noreferrer\">Rare Disease Report<\/a><\/li>\n<\/ul>\n<h4>Also in the same subject :<\/h4>\n<ul>\n<li><a title=\"Permanent Link: FDA Advisory Committee (AdCom) hears the voice of the DMD community\" href=\"\/?p=5536\" rel=\"bookmark\">FDA ADVISORY COMMITTEE (ADCOM) HEARS THE VOICE OF THE DMD COMMUNITY<\/a><\/li>\n<li><a title=\"Permanent Link: AdCom for Translarna (ataluren) by the FDA\" href=\"\/?p=5432\" rel=\"bookmark\">ADCOM FOR TRANSLARNA (ATALUREN) BY THE FDA<\/a><\/li>\n<li><a href=\"\/?page_id=3414\" target=\"_blank\" rel=\"noopener noreferrer\">Translarna\u2122 (ataluren)<\/a><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><em>#AtalurenNow #laforcedmd<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA has opted not to approve a treatment for DMD, ataluren from PTC Therapeutics. The FDA requires the PTC company to conduct yet another clinical trial in order to consider approval of the treatment. Stuart W. Peltz, CEO of PTC Therapeutics Inc., responded that a formal request called &#8220;dispute resolution&#8221; will be filed with [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":5791,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[],"class_list":["post-5765","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The FDA closes the door to the approval of ataluren<\/title>\n<meta name=\"description\" content=\"The FDA has opted not to approve a treatment for DMD, ataluren, PTC Therapeutics Inc., responded that a dispute resolution will be filed next week.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/laforcedmd.com\/en\/the-fda-closes-the-door-to-the-approval-of-ataluren\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The FDA closes the door to the approval of ataluren\" \/>\n<meta property=\"og:description\" content=\"The FDA has opted not to approve a treatment for DMD, ataluren, PTC Therapeutics Inc., responded that a dispute resolution will be filed next week.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/laforcedmd.com\/en\/the-fda-closes-the-door-to-the-approval-of-ataluren\/\" \/>\n<meta property=\"og:site_name\" content=\"La Force dmd\" \/>\n<meta property=\"article:published_time\" content=\"2017-10-26T17:25:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-03T18:19:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/laforcedmd.com\/wp-content\/uploads\/2017\/10\/the-fda-closes-the-door-to-approval-of-ataluren.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"815\" \/>\n\t<meta property=\"og:image:height\" content=\"356\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"La Force DMD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"La Force DMD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/the-fda-closes-the-door-to-the-approval-of-ataluren\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/the-fda-closes-the-door-to-the-approval-of-ataluren\\\/\"},\"author\":{\"name\":\"La Force DMD\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#\\\/schema\\\/person\\\/c7bd653b3f3d7fa23ef1721673d744cb\"},\"headline\":\"The FDA closes the door to the approval of ataluren\",\"datePublished\":\"2017-10-26T17:25:49+00:00\",\"dateModified\":\"2022-05-03T18:19:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/the-fda-closes-the-door-to-the-approval-of-ataluren\\\/\"},\"wordCount\":304,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/the-fda-closes-the-door-to-the-approval-of-ataluren\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/laforcedmd.com\\\/wp-content\\\/uploads\\\/2017\\\/10\\\/the-fda-closes-the-door-to-approval-of-ataluren.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/the-fda-closes-the-door-to-the-approval-of-ataluren\\\/\",\"url\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/the-fda-closes-the-door-to-the-approval-of-ataluren\\\/\",\"name\":\"The FDA closes the door to the approval of ataluren\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/the-fda-closes-the-door-to-the-approval-of-ataluren\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/the-fda-closes-the-door-to-the-approval-of-ataluren\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/laforcedmd.com\\\/wp-content\\\/uploads\\\/2017\\\/10\\\/the-fda-closes-the-door-to-approval-of-ataluren.jpg\",\"datePublished\":\"2017-10-26T17:25:49+00:00\",\"dateModified\":\"2022-05-03T18:19:34+00:00\",\"description\":\"The FDA has opted not to approve a treatment for DMD, ataluren, PTC Therapeutics Inc., responded that a dispute resolution will be filed next week.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/the-fda-closes-the-door-to-the-approval-of-ataluren\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/laforcedmd.com\\\/en\\\/the-fda-closes-the-door-to-the-approval-of-ataluren\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/the-fda-closes-the-door-to-the-approval-of-ataluren\\\/#primaryimage\",\"url\":\"https:\\\/\\\/laforcedmd.com\\\/wp-content\\\/uploads\\\/2017\\\/10\\\/the-fda-closes-the-door-to-approval-of-ataluren.jpg\",\"contentUrl\":\"https:\\\/\\\/laforcedmd.com\\\/wp-content\\\/uploads\\\/2017\\\/10\\\/the-fda-closes-the-door-to-approval-of-ataluren.jpg\",\"width\":815,\"height\":356},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/the-fda-closes-the-door-to-the-approval-of-ataluren\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The FDA closes the door to the approval of ataluren\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#website\",\"url\":\"https:\\\/\\\/laforcedmd.com\\\/\",\"name\":\"La Force dmd\",\"description\":\"Dystrophie musculaire de Duchenne\",\"publisher\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/laforcedmd.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#organization\",\"name\":\"La Force dmd\",\"url\":\"https:\\\/\\\/laforcedmd.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/laforcedmd.com\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/logo-la-force-dmd.jpg\",\"contentUrl\":\"https:\\\/\\\/laforcedmd.com\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/logo-la-force-dmd.jpg\",\"width\":500,\"height\":125,\"caption\":\"La Force dmd\"},\"image\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#\\\/schema\\\/person\\\/c7bd653b3f3d7fa23ef1721673d744cb\",\"name\":\"La Force DMD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1362e69258784090c887e017c49a0bab8291c910310241733859975cc5ae0c07?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1362e69258784090c887e017c49a0bab8291c910310241733859975cc5ae0c07?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1362e69258784090c887e017c49a0bab8291c910310241733859975cc5ae0c07?s=96&d=mm&r=g\",\"caption\":\"La Force DMD\"},\"url\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/author\\\/la-force-dmd\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The FDA closes the door to the approval of ataluren","description":"The FDA has opted not to approve a treatment for DMD, ataluren, PTC Therapeutics Inc., responded that a dispute resolution will be filed next week.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/laforcedmd.com\/en\/the-fda-closes-the-door-to-the-approval-of-ataluren\/","og_locale":"en_US","og_type":"article","og_title":"The FDA closes the door to the approval of ataluren","og_description":"The FDA has opted not to approve a treatment for DMD, ataluren, PTC Therapeutics Inc., responded that a dispute resolution will be filed next week.","og_url":"https:\/\/laforcedmd.com\/en\/the-fda-closes-the-door-to-the-approval-of-ataluren\/","og_site_name":"La Force dmd","article_published_time":"2017-10-26T17:25:49+00:00","article_modified_time":"2022-05-03T18:19:34+00:00","og_image":[{"width":815,"height":356,"url":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2017\/10\/the-fda-closes-the-door-to-approval-of-ataluren.jpg","type":"image\/jpeg"}],"author":"La Force DMD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"La Force DMD","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/laforcedmd.com\/en\/the-fda-closes-the-door-to-the-approval-of-ataluren\/#article","isPartOf":{"@id":"https:\/\/laforcedmd.com\/en\/the-fda-closes-the-door-to-the-approval-of-ataluren\/"},"author":{"name":"La Force DMD","@id":"https:\/\/laforcedmd.com\/#\/schema\/person\/c7bd653b3f3d7fa23ef1721673d744cb"},"headline":"The FDA closes the door to the approval of ataluren","datePublished":"2017-10-26T17:25:49+00:00","dateModified":"2022-05-03T18:19:34+00:00","mainEntityOfPage":{"@id":"https:\/\/laforcedmd.com\/en\/the-fda-closes-the-door-to-the-approval-of-ataluren\/"},"wordCount":304,"commentCount":0,"publisher":{"@id":"https:\/\/laforcedmd.com\/#organization"},"image":{"@id":"https:\/\/laforcedmd.com\/en\/the-fda-closes-the-door-to-the-approval-of-ataluren\/#primaryimage"},"thumbnailUrl":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2017\/10\/the-fda-closes-the-door-to-approval-of-ataluren.jpg","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/laforcedmd.com\/en\/the-fda-closes-the-door-to-the-approval-of-ataluren\/","url":"https:\/\/laforcedmd.com\/en\/the-fda-closes-the-door-to-the-approval-of-ataluren\/","name":"The FDA closes the door to the approval of ataluren","isPartOf":{"@id":"https:\/\/laforcedmd.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/laforcedmd.com\/en\/the-fda-closes-the-door-to-the-approval-of-ataluren\/#primaryimage"},"image":{"@id":"https:\/\/laforcedmd.com\/en\/the-fda-closes-the-door-to-the-approval-of-ataluren\/#primaryimage"},"thumbnailUrl":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2017\/10\/the-fda-closes-the-door-to-approval-of-ataluren.jpg","datePublished":"2017-10-26T17:25:49+00:00","dateModified":"2022-05-03T18:19:34+00:00","description":"The FDA has opted not to approve a treatment for DMD, ataluren, PTC Therapeutics Inc., responded that a dispute resolution will be filed next week.","breadcrumb":{"@id":"https:\/\/laforcedmd.com\/en\/the-fda-closes-the-door-to-the-approval-of-ataluren\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/laforcedmd.com\/en\/the-fda-closes-the-door-to-the-approval-of-ataluren\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/laforcedmd.com\/en\/the-fda-closes-the-door-to-the-approval-of-ataluren\/#primaryimage","url":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2017\/10\/the-fda-closes-the-door-to-approval-of-ataluren.jpg","contentUrl":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2017\/10\/the-fda-closes-the-door-to-approval-of-ataluren.jpg","width":815,"height":356},{"@type":"BreadcrumbList","@id":"https:\/\/laforcedmd.com\/en\/the-fda-closes-the-door-to-the-approval-of-ataluren\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/laforcedmd.com\/en\/"},{"@type":"ListItem","position":2,"name":"The FDA closes the door to the approval of ataluren"}]},{"@type":"WebSite","@id":"https:\/\/laforcedmd.com\/#website","url":"https:\/\/laforcedmd.com\/","name":"La Force dmd","description":"Dystrophie musculaire de Duchenne","publisher":{"@id":"https:\/\/laforcedmd.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/laforcedmd.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/laforcedmd.com\/#organization","name":"La Force dmd","url":"https:\/\/laforcedmd.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/laforcedmd.com\/#\/schema\/logo\/image\/","url":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2022\/06\/logo-la-force-dmd.jpg","contentUrl":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2022\/06\/logo-la-force-dmd.jpg","width":500,"height":125,"caption":"La Force dmd"},"image":{"@id":"https:\/\/laforcedmd.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/laforcedmd.com\/#\/schema\/person\/c7bd653b3f3d7fa23ef1721673d744cb","name":"La Force DMD","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/1362e69258784090c887e017c49a0bab8291c910310241733859975cc5ae0c07?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1362e69258784090c887e017c49a0bab8291c910310241733859975cc5ae0c07?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1362e69258784090c887e017c49a0bab8291c910310241733859975cc5ae0c07?s=96&d=mm&r=g","caption":"La Force DMD"},"url":"https:\/\/laforcedmd.com\/en\/author\/la-force-dmd\/"}]}},"_links":{"self":[{"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/posts\/5765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/comments?post=5765"}],"version-history":[{"count":1,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/posts\/5765\/revisions"}],"predecessor-version":[{"id":11204,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/posts\/5765\/revisions\/11204"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/media\/5791"}],"wp:attachment":[{"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/media?parent=5765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/categories?post=5765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/tags?post=5765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}